Skip to main content
Jeffrey Myers, MD, Otolaryngology (ENT), Houston, TX

JeffreyN.MyersMD

Otolaryngology (ENT) Houston, TX

Associate Professor of Otolaryngology, University Tex Houston

Dr. Myers is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Myers' full profile

Already have an account?

  • Office

    1515 Holcombe Blvd
    Houston, TX 77030
    Phone+1 713-792-6161

Education & Training

  • UPMC Medical Education (Pittsburgh)
    UPMC Medical Education (Pittsburgh)Residency, Otolaryngology - Head and Neck Surgery, 1992 - 1996
  • UPMC Medical Education
    UPMC Medical EducationInternship, Transitional Year, 1991 - 1992
  • Perelman School of Medicine at the University of Pennsylvania
    Perelman School of Medicine at the University of PennsylvaniaClass of 1991
  • University of Pennsylvania
    University of PennsylvaniaPh.D., Biochemistry, 1991
  • University of Pennsylvania
    University of PennsylvaniaB.A., Biochemistry, 1983

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • TX State Medical License
    TX State Medical License 1998 - 2026
  • OK State Medical License
    OK State Medical License 2020 - 2021
  • PA State Medical License
    PA State Medical License 1993 - 2000
  • American Board of Otolaryngology - Head and Neck Surgery Otolaryngology

Awards, Honors, & Recognition

  • Fellow American Association for the Advancement of Science (AAAS), 2017
  • Best Doctors in America Best Doctors, Inc., 2017
  • MedCity - Houston Top Doctors Houston Chronicle, 2016
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • PI3‐Kinase Pathway Biomarkers in Oral Cancer and Tumor Immune Cells  
    Bonnie S Glisson, Jeffrey Myers, N Jr William, Renata Ferrarotto, Head & Neck
  • Outcomes of Microvascular Flap Reconstruction of the Head and Neck in Patients Receiving Systemic Immunosuppressive Therapy for Organ Transplantation  
    Peirong Yu, Jeffrey N Myers, Journal of Surgical Oncology
  •  
    Lam-Ubol A, Fitzgerald AL, Ritdej A, Phonyiam T, Zhang H, Myers JN, Huang P, Trachootham D, Royal Society of Chemistry - Food and Function, 1/1/2018
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Immunohistochemical Expression of Hormone Receptors in Melanoma of Pregnant Women, Non-pregnant Women and Men: a Comparison Study.
    Zhou JH, Kim KB, Fox P, Myers JN, Prieto VG, United States and Canadian Academy of Pathology 102nd Annual Meeting, 1/1/2013
  • MK-1775, A Selective wee1 Kinase Inhibitor, Overcomes Cisplatin Resistance Associated with High Risk TP53 Mutations in Squamous Cell Carcinoma of the Head and Neck.
    Osman AA, Alves MO, Neskey DM, Monroe MM, Patel AA, Chuang H, Mason L, Meyn RE, Byers LA, Katsonis P, Lichtarge O, Myers JN, American Association of Cancer Research Annual Meeting, 1/1/2013
  • SOCS2 (Suppressor of Cytokine Signaling Protein 2) is a Prognostic Indicator of Progression-Free Survival in Head and Neck Squamous Cell Carcinoma (HNSCC) Patients.
    Nicholas C, Nunez MI, Harun N, Lee JJ, Myers JN, Wistuba II, Sen B, El-Naggar AK, Lai SY, Johnson FM, William WN, American Association for Cancer Research, 1/1/2013
  • Join now to see all

Lectures

  • Myers JN. Multi-Disciplinary Head & Neck Cancer Care in 2018 
    University of Arkansas for Medical Sciences, Little Rock, AR - 1/16/2018
  • The Role of the Otolaryngologist - Head and Neck Surgeon in Oropharyngeal Cancer Management 
    University of Arkansas for Medical Sciences, Little Rock, AR - 1/16/2018
  • Personalizing HNSCC treatment based on TP53 mutational status 
    San Diego, CA - 1/24/2017
  • Join now to see all

Press Mentions

  • Lifechanging New Cancer Therapy Kills 99% of Cancer Cells
    Lifechanging New Cancer Therapy Kills 99% of Cancer CellsOctober 29th, 2024
  • Molecular Jackhammers Drill Pathway to Killing Cancer Cells
    Molecular Jackhammers Drill Pathway to Killing Cancer CellsJanuary 21st, 2024

Grant Support

  • Progression And Metastasis Of Oral Tongue CancerNational Institute Of Dental &Craniofacial Research2009–2012
  • Comprehensive Analysis Of Genetic Alterations In Oral CancerNational Institute Of Dental &Craniofacial Research2009–2010
  • Training Of Academic Head And Neck Surgical OncologistNational Cancer Institute2004–2010
  • The 7th International Conference On Head And Neck CancerNational Institute Of Dental &Craniofacial Research2008
  • Progression Of Metastasis Of Oral Tongue CancerNational Institute Of Dental &Craniofacial Research2003–2007
  • Targeting Angiogenesis For Therapy Of Head And Neck CancerNational Cancer Institute2002

Professional Memberships